person · Reporting owner

COLELLA SAMUEL D

Disclosed activity across 2 companies

Tapewire entity: 133272
SEC CIK: 0001201580

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
STANDARD BIOTOOLS INC.FLDM · Entity 6116	Director	March 10, 2020	March 13, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

STANDARD BIOTOOLS INC.

Report date March 10, 2020 · Filed March 13, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	161,109	Ending reported balance After 2020-03-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-03-10 · Purchase · Acquired 10,000 · Balance 151,109 F1: The range of prices for the transactions reported is between $2.755 and $2.78 per share. $2.7738 represents the weighted average purchase price per share. The Reporting Person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price. Row 2 · 2020-03-11 · Purchase · Acquired 10,000 · Balance 161,109 F2: The range of prices for the transactions reported is between $2.645 and $2.67 per share. $2.6545 represents the weighted average purchase price per share. The Reporting Person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price.
Common StockSEC Table I · non-derivative	IndirectColella Family Partners, L.P	5,561	Reported balance Holding disclosure · report date 2020-03-10 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 5,561 F3: The shares are held by Colella Family Partners, L.P., of which the Reporting Person is the General Partner. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectColella Family Exempt Marital Deduction Trust dated 9/21/1992	69,272	Reported balance Holding disclosure · report date 2020-03-10 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 69,272
Common StockSEC Table I · non-derivative	IndirectColella Family Non-Exempt Marital Deduction Trust dated 9/21/1992	3,326	Reported balance Holding disclosure · report date 2020-03-10 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 3,326

Filing footnotes · ownership attribution and instrument terms

F1: The range of prices for the transactions reported is between $2.755 and $2.78 per share. $2.7738 represents the weighted average purchase price per share. The Reporting Person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price.

F2: The range of prices for the transactions reported is between $2.645 and $2.67 per share. $2.6545 represents the weighted average purchase price per share. The Reporting Person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price.

F3: The shares are held by Colella Family Partners, L.P., of which the Reporting Person is the General Partner. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein, if any.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Flexion Therapeutics Inc

Report date November 19, 2021 · Filed November 19, 2021

Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-11-19 transaction · row 1 1 source row Row 1 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. F3: 2,198 shares were inadvertently reported as held directly by the Reporting Person. The shares are held by the Colella Family Trust UTA dtd 9/21/92.
Common StockSEC Table I · non-derivative	IndirectThe Samuel Colella Trust	Reported balance After 2021-11-19 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-11-19 · Disposition to issuer · Disposed 1,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
Common StockSEC Table I · non-derivative	IndirectBy the Colella Family Trust	Reported balance After 2021-11-19 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-11-19 · Disposition to issuer · Disposed 72,035 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F3: 2,198 shares were inadvertently reported as held directly by the Reporting Person. The shares are held by the Colella Family Trust UTA dtd 9/21/92. F4: The shares are held by the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust"). The Reporting Person is a trustee and beneficiary of the Colella Trust.
Common StockSEC Table I · non-derivative	IndirectBy the Colella Family Exempt Marital Deduction Trust	Reported balance After 2021-11-19 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2021-11-19 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F5: The shares are held by the Colella Family Exempt Marital Deduction Trust Dated 9/21/1992 ("Colella Exempt Trust"). The Reporting Person is a trustee and beneficiary of the Colella Exempt Trust.
Common StockSEC Table I · non-derivative	IndirectBy Versant Venture Capital III L.P.	Reported balance After 2021-11-19 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2021-11-19 · Disposition to issuer · Disposed 994,129 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F6: The shares are held by Versant Venture Capital III, L.P. ("VVC III"). The Reporting Person is a managing member of Versant Ventures III, LLC ("VV III"), the sole general partner of VVC III and shares voting and dispositive power over the shares held by VVC III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectBy Versant Side Fund III	Reported balance After 2021-11-19 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2021-11-19 · Disposition to issuer · Disposed 5,871 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F7: The shares are held by Versant Side Fund III, L.P. ("Side Fund III"). The Reporting Person is a managing member of VV III, the sole general partner of Side Fund III and shares voting and dispositive power over the shares held by Side Fund III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectBy Versant Development Fund III, LLC	Reported balance After 2021-11-19 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2021-11-19 · Disposition to issuer · Disposed 388,683 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F8: The shares are held by Versant Development Fund III, LLC ("Development III"). The Reporting Person is a managing member of VV III, a majority member of Development III and shares voting and dispositive power over the shares held by Development III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectBy Colella Partners	Reported balance After 2021-11-19 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2021-11-19 · Disposition to issuer · Disposed 943 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F9: Shares held by Colella Partners. The Reporting Person is the general partner of Colella Partners.
Common StockSEC Table I · non-derivative	IndirectBy Colella Partners II	Reported balance After 2021-11-19 transaction · row 9 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 9 · 2021-11-19 · Disposition to issuer · Disposed 19,653 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F10: Shares held by Colella Partners II. The Reporting Person is the general partner of Colella Partners II.
Common StockSEC Table I · non-derivative	IndirectBy spouse	Reported balance After 2021-11-19 transaction · row 10 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 10 · 2021-11-19 · Disposition to issuer · Disposed 250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.61 · Expires 2024-03-02	Direct	Reported balance After 2021-11-19 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.85 · Expires 2025-06-16	Direct	Reported balance After 2021-11-19 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2026-06-09	Direct	Reported balance After 2021-11-19 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.16 · Expires 2027-06-21	Direct	Reported balance After 2021-11-19 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.14 · Expires 2028-06-19	Direct	Reported balance After 2021-11-19 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.74 · Expires 2029-06-18	Direct	Reported balance After 2021-11-19 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09	Direct	Reported balance After 2021-11-19 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.22 · Expires 2031-06-23	Direct	Reported balance After 2021-11-19 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.

F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.

F3: 2,198 shares were inadvertently reported as held directly by the Reporting Person. The shares are held by the Colella Family Trust UTA dtd 9/21/92.

F4: The shares are held by the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust"). The Reporting Person is a trustee and beneficiary of the Colella Trust.

F5: The shares are held by the Colella Family Exempt Marital Deduction Trust Dated 9/21/1992 ("Colella Exempt Trust"). The Reporting Person is a trustee and beneficiary of the Colella Exempt Trust.

F6: The shares are held by Versant Venture Capital III, L.P. ("VVC III"). The Reporting Person is a managing member of Versant Ventures III, LLC ("VV III"), the sole general partner of VVC III and shares voting and dispositive power over the shares held by VVC III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.

F7: The shares are held by Versant Side Fund III, L.P. ("Side Fund III"). The Reporting Person is a managing member of VV III, the sole general partner of Side Fund III and shares voting and dispositive power over the shares held by Side Fund III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.

F8: The shares are held by Versant Development Fund III, LLC ("Development III"). The Reporting Person is a managing member of VV III, a majority member of Development III and shares voting and dispositive power over the shares held by Development III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.

F9: Shares held by Colella Partners. The Reporting Person is the general partner of Colella Partners.

F10: Shares held by Colella Partners II. The Reporting Person is the general partner of Colella Partners II.

F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	7,000	Not disclosed Strike: $9.22	Not disclosed	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · derivative · entry 18 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2031-06-23 F11 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F11 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	7,000	Not disclosed Strike: $11.88	Not disclosed	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · derivative · entry 17 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2030-06-09 F11 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F11 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	12,500	Not disclosed Strike: $11.74	Not disclosed	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · derivative · entry 16 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2029-06-18 F11 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F11 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	12,500	Not disclosed Strike: $28.14	Not disclosed	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · derivative · entry 15 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2028-06-19 F11 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F11 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	12,500	Not disclosed Strike: $20.16	Not disclosed	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · derivative · entry 14 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F11 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F11 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	12,500	Not disclosed Strike: $13.83	Not disclosed	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · derivative · entry 13 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2026-06-09 F11 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F11 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	9,000	Not disclosed Strike: $21.85	Not disclosed	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · derivative · entry 12 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2025-06-16 F11 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F11 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	9,000	Not disclosed Strike: $17.61	Not disclosed	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · derivative · entry 11 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2024-03-02 F11 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F11 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	250	$8.50	$2,125.00	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · nonDerivative · entry 10 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	19,653	$8.50	$167,050.50	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · nonDerivative · entry 9 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Colella Partners II Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F10 · ownership.nature: Shares held by Colella Partners II. The Reporting Person is the general partner of Colella Partners II. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	943	$8.50	$8,015.50	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · nonDerivative · entry 8 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Colella Partners Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F9 · ownership.nature: Shares held by Colella Partners. The Reporting Person is the general partner of Colella Partners. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	388,683	$8.50	$3,303,805.50	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · nonDerivative · entry 7 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Versant Development Fund III, LLC Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F8 · ownership.nature: The shares are held by Versant Development Fund III, LLC ("Development III"). The Reporting Person is a managing member of VV III, a majority member of Development III and shares voting and dispositive power over the shares held by Development III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	5,871	$8.50	$49,903.50	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · nonDerivative · entry 6 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Versant Side Fund III Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F7 · ownership.nature: The shares are held by Versant Side Fund III, L.P. ("Side Fund III"). The Reporting Person is a managing member of VV III, the sole general partner of Side Fund III and shares voting and dispositive power over the shares held by Side Fund III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	994,129	$8.50	$8,450,096.50	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · nonDerivative · entry 5 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Versant Venture Capital III L.P. Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F6 · ownership.nature: The shares are held by Versant Venture Capital III, L.P. ("VVC III"). The Reporting Person is a managing member of Versant Ventures III, LLC ("VV III"), the sole general partner of VVC III and shares voting and dispositive power over the shares held by VVC III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	5,000	$8.50	$42,500.00	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · nonDerivative · entry 4 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Colella Family Exempt Marital Deduction Trust Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F5 · ownership.nature: The shares are held by the Colella Family Exempt Marital Deduction Trust Dated 9/21/1992 ("Colella Exempt Trust"). The Reporting Person is a trustee and beneficiary of the Colella Exempt Trust. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	72,035	$8.50	$612,297.50	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · nonDerivative · entry 3 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Colella Family Trust Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F3 · shares: 2,198 shares were inadvertently reported as held directly by the Reporting Person. The shares are held by the Colella Family Trust UTA dtd 9/21/92. F4 · ownership.nature: The shares are held by the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust"). The Reporting Person is a trustee and beneficiary of the Colella Trust. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	1,000	$8.50	$8,500.00	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Samuel Colella Trust Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:12 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	9,000	$8.50	$76,500.00	Disclosure SEC source: 0001209191-21-065716 · doc4.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2 · shares: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. F3 · shares: 2,198 shares were inadvertently reported as held directly by the Reporting Person. The shares are held by the Colella Family Trust UTA dtd 9/21/92. Read SEC document
June 24, 2021 Filed Jun 28, 2021 18:32 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantStock option (right to buy) · Derivative	7,000	$0.00 Strike: $9.22	$0.00	Disclosure SEC source: 0001209191-21-043553 · doc4.xml · derivative · entry 11 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-06-23 F10 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document
June 24, 2021 Filed Jun 28, 2021 18:32 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0001209191-21-043553 · doc4.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,198 F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. F2 · balance_after: Reflects the transfer of 1,000 shares to The Samuel Colella Trust. Read SEC document
January 15, 2021 Filed Jan 20, 2021 19:09 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	OtherCommon Stock	943	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002552 · doc4.xml · nonDerivative · entry 7 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 943 F12 · kind: Represents a change in the form of ownership of Colella Family Partners ("Colella Partners") by virtue of the receipt of shares in the pro-rata distribution of common stock of the Issuer for no consideration by VSF III. F13 · ownership.nature: Shares held by Colella Partners. The Reporting Person is the general partner of Colella Partners. Read SEC document
January 15, 2021 Filed Jan 20, 2021 19:09 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	OtherCommon Stock	2,198	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002552 · doc4.xml · nonDerivative · entry 6 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,531 F10 · kind: Represents a change in the form of ownership of the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust") by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VSF III. F11 · ownership.nature: Shares held by Colella Trust. The Reporting Person, a member of the Issuer's board of directors, is a trustee and beneficiary of the Colella Trust. Read SEC document
January 15, 2021 Filed Jan 20, 2021 19:09 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	OtherCommon Stock	14,868	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002552 · doc4.xml · nonDerivative · entry 5 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,871 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund III, L.P. ("VSF III"), to its partners. F9 · ownership.nature: Shares held by VSF III. VV III is the sole general partner of VSF III. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV III and may be deemed to share voting and dispositive power over the shares held by VSF III. Each of VV III and the Reporting Person disclaims beneficial ownership of the shares held by VSF III, except to the extent of their respective pecuniary interests therein. Read SEC document
January 15, 2021 Filed Jan 20, 2021 19:09 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	OtherCommon Stock	19,653	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002552 · doc4.xml · nonDerivative · entry 4 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 19,653 F6 · kind: Represents a change in the form of ownership of Colella Partners II, L.P. ("Colella Partners II") by virtue of the receipt of shares in the pro-rata distribution of common stock of the Issuer for no consideration by VV III. F7 · ownership.nature: Shares held by Colella Partners II. The Reporting Person is the general partner of Colella Partners II. Read SEC document
January 15, 2021 Filed Jan 20, 2021 19:09 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	OtherCommon Stock	648,266	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002552 · doc4.xml · nonDerivative · entry 3 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV III, to its members. F4 · ownership.nature: Shares held by VV III. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV III and may be deemed to share voting and dispositive power over the shares held by VV III; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document
January 15, 2021 Filed Jan 20, 2021 19:09 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	OtherCommon Stock	648,266	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002552 · doc4.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 648,266 F3 · kind: Represents a change in the form of ownership of VV III by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VVC III. F4 · ownership.nature: Shares held by VV III. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV III and may be deemed to share voting and dispositive power over the shares held by VV III; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document
January 15, 2021 Filed Jan 20, 2021 19:09 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	OtherCommon Stock	2,517,541	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002552 · doc4.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 994,129 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital III, L.P. ("VVC III"), to its partners. F2 · ownership.nature: Shares held by VVC III. Versant Ventures III, LLC ("VV III") is the sole general partner of VVC III. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV III and may be deemed to share voting and dispositive power over the shares held by VVC III. Each of VV III and the Reporting Person disclaims beneficial ownership of the shares held by VVC III, except to the extent of their respective pecuniary interests therein. Read SEC document
January 15, 2021 Filed Mar 12, 2021 17:10 UTC Amendment	Flexion Therapeutics Inc FLXN · Entity 16545	OtherCommon Stock	2,198	$0.00	$0.00	Disclosure SEC source: 0001209191-21-020224 · doc4a.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 69,837 F1 · kind: Represents a change in the form of ownership of the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust") by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Side Fund III, L.P. to its partners. F2 · balance_after: 24,504 shares held by the Reporting Person were inadvertently reported on prior Form 4 filings as held directly. Instead, the shares are held by the Reporting Person indirectly in the name of the Colella Trust. F3 · balance_after: 2,198 shares were inadvertently reported as held by the Colella Trust. The shares are held directly by the Reporting Person. F4 · ownership.nature: Shares held by the Colella Trust. The Reporting Person, a member of the Issuer's board of directors, is a trustee and beneficiary of the Colella Trust. Read SEC document
June 10, 2020 Filed Jun 12, 2020 16:13 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantStock option (right to buy) · Derivative	7,000	$0.00 Strike: $11.88	$0.00	Disclosure SEC source: 0001209191-20-036251 · doc4.xml · derivative · entry 7 COLELLA SAMUEL D · CIK 0001201580 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-06-09 F7 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document
June 10, 2020 Filed Jun 12, 2020 16:13 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0001209191-20-036251 · doc4.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,004 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document
March 11, 2020 Filed Mar 13, 2020 01:28 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	PurchaseCommon Stock	10,000	$2.65	$26,545.00	Disclosure SEC source: 0001162194-20-000027 · wf-form4_158406288398220.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,109 F2 · price: The range of prices for the transactions reported is between $2.645 and $2.67 per share. $2.6545 represents the weighted average purchase price per share. The Reporting Person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document
March 10, 2020 Filed Mar 13, 2020 01:28 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	PurchaseCommon Stock	10,000	$2.77	$27,738.00	Disclosure SEC source: 0001162194-20-000027 · wf-form4_158406288398220.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,109 F1 · price: The range of prices for the transactions reported is between $2.755 and $2.78 per share. $2.7738 represents the weighted average purchase price per share. The Reporting Person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document
February 04, 2020 Filed Feb 7, 2020 00:00 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	GrantCommon Stock	21,628	$0.00	$0.00	Disclosure SEC source: 0001162194-20-000003 · wf-form4_158103361803794.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,109 F1 · shares: Represents Restricted Stock Units that vest in four equal quarterly installments beginning March 31, 2020. Read SEC document
August 27, 2019 Filed Aug 29, 2019 01:13 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	PurchaseCommon Stock	2,000	$5.19	$10,371.80	Disclosure SEC source: 0001162194-19-000086 · wf-form4_156704121821246.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,481 Read SEC document
August 08, 2019 Filed Aug 9, 2019 16:05 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	PurchaseCommon Stock	2,000	$10.74	$21,480.00	Disclosure SEC source: 0001209191-19-045325 · doc4.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the Colella Family Trust Disclosed balance after: 45,333 F1 · price: The weighted average purchase price for the transaction reported was $10.74, and the range of prices were between $10.735 and $10.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · ownership.nature: The shares are held by the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust"). The Reporting Person is a trustee and beneficiary of the Colella Trust. Read SEC document
August 08, 2019 Filed Aug 12, 2019 20:57 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	PurchaseCommon Stock	1,000	$6.65	$6,653.30	Disclosure SEC source: 0001162194-19-000074 · wf-form4_156564343873081.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,481 Read SEC document
August 07, 2019 Filed Aug 9, 2019 01:04 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	PurchaseCommon Stock	1,000	$6.86	$6,856.70	Disclosure SEC source: 0001162194-19-000071 · wf-form4_156531266138292.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,481 Read SEC document
August 06, 2019 Filed Aug 9, 2019 01:04 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	PurchaseCommon Stock	8,000	$7.02	$56,183.20	Disclosure SEC source: 0001162194-19-000071 · wf-form4_156531266138292.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,481 F1 · price: The range of prices for the transactions reported is between $7.01 and $7.03 per share. $7.0229 represents the weighted average purchase price per share. Reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document
June 20, 2019 Filed Jun 25, 2019 01:14 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	Exercise / conversionStock Option (Right to Buy) · Derivative	10,600	$5.57 Strike: $5.57	$59,042.00	Disclosure SEC source: 0001162194-19-000060 · wf-form4_156142522706670.xml · derivative · entry 11 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,600 shares Expires 2028-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The Option vested and became exercisable in twelve equal monthly increments and was fully exercisable on May 31, 2019. Read SEC document
June 20, 2019 Filed Jun 25, 2019 01:14 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$3.43 Strike: $3.43	$17,150.00	Disclosure SEC source: 0001162194-19-000060 · wf-form4_156142522706670.xml · derivative · entry 10 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Option vested and became exercisable in twelve equal monthly increments and was fully exercisable on August 1, 2018. Read SEC document
June 20, 2019 Filed Jun 25, 2019 01:14 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	Exercise / conversionStock Option (Right to Buy) · Derivative	3,000	$5.44 Strike: $5.44	$16,320.00	Disclosure SEC source: 0001162194-19-000060 · wf-form4_156142522706670.xml · derivative · entry 9 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2027-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Option vested and became exercisable in twelve equal monthly increments and was fully exercisable on August 1, 2018. Read SEC document
June 20, 2019 Filed Jun 25, 2019 01:14 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$10.45 Strike: $10.45	$52,250.00	Disclosure SEC source: 0001162194-19-000060 · wf-form4_156142522706670.xml · derivative · entry 8 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Option vested and became exercisable in twelve equal monthly increments and was fully exercisable on August 3, 2017. Read SEC document
June 20, 2019 Filed Jun 25, 2019 01:14 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	Exercise / conversionCommon Stock	10,600	$5.57	$59,042.00	Disclosure SEC source: 0001162194-19-000060 · wf-form4_156142522706670.xml · nonDerivative · entry 4 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 20, 2019 Filed Jun 25, 2019 01:14 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	Exercise / conversionCommon Stock	5,000	$3.43	$17,150.00	Disclosure SEC source: 0001162194-19-000060 · wf-form4_156142522706670.xml · nonDerivative · entry 3 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 20, 2019 Filed Jun 25, 2019 01:14 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	Exercise / conversionCommon Stock	3,000	$5.44	$16,320.00	Disclosure SEC source: 0001162194-19-000060 · wf-form4_156142522706670.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 20, 2019 Filed Jun 25, 2019 01:14 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	Exercise / conversionCommon Stock	5,000	$10.45	$52,250.00	Disclosure SEC source: 0001162194-19-000060 · wf-form4_156142522706670.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects an aggregate of 15,877 shares that were reported in prior Forms 4 as being directly held and are now being reported as indirectly held. Of such 15,877 shares, (i) 10,877 shares were transferred to the Colella Family Exempt Marital Deduction Trust dated 9/21/1992 (the "Trust") for no consideration on July 25, 2016, and (ii) 5,000 shares were acquired by the Trust in an open market purchase on December 14, 2016, that was erroneously reported as a direct ownership transaction. Read SEC document
June 19, 2019 Filed Jun 21, 2019 16:08 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantStock option (right to buy) · Derivative	12,500	$0.00 Strike: $11.74	$0.00	Disclosure SEC source: 0001209191-19-038458 · doc4.xml · derivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-06-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document
June 03, 2019 Filed Jun 5, 2019 17:40 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	GrantStock Option (Right to Buy) · Derivative	6,796	$0.00 Strike: $13.41	$0.00	Disclosure SEC source: 0001162194-19-000051 · wf-form4_155975638004967.xml · derivative · entry 5 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,796 Underlying: Common Stock · 6,796 shares Expires 2029-06-03 F3 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly installments beginning on July 3, 2019. Read SEC document
June 03, 2019 Filed Jun 5, 2019 17:40 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	GrantCommon Stock	3,987	$0.00	$0.00	Disclosure SEC source: 0001162194-19-000051 · wf-form4_155975638004967.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,758 F1 · shares: Represents Restricted Stock Units that vest in full on the earlier to occur of June 3, 2020 and one day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document
February 12, 2019 Filed Feb 15, 2019 02:03 UTC	STANDARD BIOTOOLS INC. FLDM · Entity 6116	GrantCommon Stock	9,748	$0.00	$0.00	Disclosure SEC source: 0001162194-19-000007 · wf-form4_155019617000141.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,771 F1 · shares: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. Subject to the Reporting Person's continued service with the Issuer through each applicable vesting date, twenty-five percent (25%) of the shares underlying the Restricted Stock Units shall vest quarterly on the last day of each quarter during 2019. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.